Stock comparison
Genmab A/S
Harmony Biosciences Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
Overall winner
Harmony Biosciences Holdings HRMY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | HRMY | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 67B | HRMY |
| Benjamin Graham | 64C | 60C | GMAB |
| Philip Fisher | 48D | 75B | HRMY |
| Peter Lynch | 25F | 62C | HRMY |
| Joel Greenblatt | 76B | 28F | GMAB |
| Charlie Munger | 68C | 62C | GMAB |
| Terry Smith | 71C | 67B | GMAB |
Side-by-side metrics
| Metric | GMAB | HRMY |
|---|---|---|
| Market cap | $16.5B | $1.75B |
| P/E (TTM) | 6.2x | 11.8x |
| EV/EBIT | 12.0x | 6.4x |
| ROIC (TTM) | 43.78% | 12.5% |
| Gross margin | 93.88% | 76.55% |
| Net margin | 18.23% | 16.2% |
| Revenue CAGR 5y | -18.45% | 29.85% |
| EPS CAGR 5y | -23.48% | 46.45% |
| Debt / Equity | 0.1x | 0.2x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Market cap$16.5Bvs $1.75B+89%
- ROIC (TTM)43.78%vs 12.5%+71%
- Debt / Equity0.1xvs 0.2x+68%
- P/E (TTM)6.2xvs 11.8x+48%
HRMY leads on
- Revenue CAGR 5y29.85%vs -18.45%+162%
- EPS CAGR 5y46.45%vs -23.48%+151%
- EV/EBIT6.4xvs 12.0x+46%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.